Evidence map›Paper›PMID 30053044›Full record

ReviewJournal of the Pediatric Infectious Diseases Society2019

Update on Associated Risk Factors, Diagnosis, and Management of Recurrent Urinary Tract Infections in Children.

Anum Khan, Ravi Jhaveri, Patrick C Seed, Mehreen Arshad

Registry-linked trialAbstract readReview
In one paragraph

Review in Journal of the Pediatric Infectious Diseases Society, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07508124 (Topical Steroids to Prevent Recurrent Urinary Tract Infections in Uncircumcised Male Infants With a First Febrile Urinary Tract Infection), which is not on this map. Cited by 19 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 2 pooled it
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07508124 phase4recruitingnot on this mapstarted 2026, after this paper: background citation

Topical Steroids to Prevent Recurrent Urinary Tract Infections in Uncircumcised Male Infants With a First Febrile Urinary Tract Infection: a Multi-center Pilot Study

TypeinterventionalSponsorBaylor College of MedicineRan2026 to 2027Enrolled40ConditionsUrinary Tract InfectionArmsbetamethasone valerate 0.1% cream, Placebo cream
3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 47 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Microorganisms · 2024
    Article
  7. Article
  8. Article
  9. Review
  10. Phenotypic and genotypic characteristics ofFrontiers in public health · 2023
    Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 2 countries.

Anum KhanSchool of Medicine, Allama Iqbal Medical College, Lahore, Pakistan.
Ravi JhaveriDivision of Infectious Diseases, Department of Pediatrics, University of North Carolina at Chapel Hill School of Medicine.
Patrick C SeedAnn and Robert H. Lurie Children's Hospital and Stanley Manne Children's Research Institute, Chicago, Illinois.
Mehreen ArshadDivision of Infectious Diseases, Department of Pediatrics, Duke University School of Medicine, Durham, North Carolina.
Allama Iqbal Medical College · PKDuke University · USLurie Children's Hospital · USUniversity of North Carolina at Chapel Hill · US

Funding

Center for Molecular &Cellular Studies of Ped DiseaseK12HD043494 · NICHD · DUKE UNIVERSITY · PI REED, ANN M. · 2003 to 2017
$5.2M
NICHD NIH HHS K12 HD043494
6 · The paper itself

Abstract

Recurrent urinary tract infection (rUTI) continues to challenge pediatric care providers. The diagnosis of an rUTI can be difficult, especially in young febrile children. Antibiotic resistance rates continue to rise, which limits oral treatment options. Prophylactic antibiotics are used commonly to manage rUTI, but their use increases the risk of rUTI with antibiotic-resistant strains without significantly reducing renal scarring. Alternative therapies for rUTI include probiotics and anthocyanidins (eg, cranberry extract) to reduce gut colonization by uropathogens and prevent bacterial adhesion to uroepithelia, but efficacy data for these treatments are sparse. The future of rUTI care rests in addressing the following contemporary issues: best diagnostic practices, risk factors associated with rUTI, and the prevention of recurrent infection. In this review, we summarize the state of the art for each of these issues and highlight future studies that will aim to take an alternative approach to managing rUTI.

Indexed as

AnthocyaninsAnti-Bacterial AgentsAntibiotic ProphylaxisBacterial AdhesionCircumcision, MaleDrug Resistance, MicrobialFruit and Vegetable JuicesHumansMaleProbioticsRecurrenceRisk FactorsUrinary Bladder DiseasesUrinary Tract InfectionsVaccinesVaccinium macrocarponAnthocyaninsAnti-Bacterial AgentsVaccinesantibiotic resistancediagnosisprobioticsrecurrent UTI

Identifiers

PMID30053044
PMCPMC6510945
OpenAlexW2884047970

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.